TG Therapeutics, Inc.

TG Therapeutics focuses on developing treatments for B-cell mediated diseases. They provide BRIUMVI for relapsing multiple sclerosis treatment. Their pipeline includes Umbralisib for lymphoma and TG-1701/TG-1801, orally available BTK inhibitors. The company has license agreements with LFB Biotechnologies, GTC Biotherapeutics, and others for umbralisib development. They also have a collaboration agreement with Checkpoint Therapeutics for anti-PD-L1 and anti-GITR antibody research programs. TG Therapeutics was incorporated in 1993 and is based in Morrisville, North Carolina. The company has a range of investigational medicines in its research pipeline.

Overview

Sector

Biotechnology

Target Price

2.6 USD

Current Price

36.3 USD

Potential

-93%

Strengths

No significant strengths identified based on the analyzed metrics.

Weaknesses

With a depreciation Potential of -92.64%, based on our fundamental analysis, it suggests the stock may be overvalued.
Current Price to Earnings Ratio (239.86) is significantly higher than the sector mean (91.15).
The company has high debt. Net Debt to EBITDA Ratio (1.48) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EV/EBITDA (113.87) is significantly higher than the sector mean (85.60).
EV/EBIT (114.51) is significantly higher than the sector mean.

Key Financial Data

Indicator	Value
PER	235.5
EV/EBITDA	111.8
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	1.5